AU2014219026B2 - ABCB5(+) stem cells for treating ocular disease - Google Patents

ABCB5(+) stem cells for treating ocular disease Download PDF

Info

Publication number
AU2014219026B2
AU2014219026B2 AU2014219026A AU2014219026A AU2014219026B2 AU 2014219026 B2 AU2014219026 B2 AU 2014219026B2 AU 2014219026 A AU2014219026 A AU 2014219026A AU 2014219026 A AU2014219026 A AU 2014219026A AU 2014219026 B2 AU2014219026 B2 AU 2014219026B2
Authority
AU
Australia
Prior art keywords
abcb5
stem cells
cells
ocular
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014219026A
Other languages
English (en)
Other versions
AU2014219026A1 (en
Inventor
Markus H. Frank
Natasha Y. Frank
Paraskevi Evi KOLOVOU
Bruce KSANDER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Schepens Eye Research Institute Inc
US Department of Veterans Affairs
Original Assignee
Boston Childrens Hospital
Schepens Eye Research Institute Inc
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital, Schepens Eye Research Institute Inc, US Department of Veterans Affairs filed Critical Boston Childrens Hospital
Publication of AU2014219026A1 publication Critical patent/AU2014219026A1/en
Assigned to CHILDREN'S MEDICAL CENTER CORPORATION, SCHEPENS EYE RESEARCH INSTITUTE, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERAN AFFAIRS reassignment CHILDREN'S MEDICAL CENTER CORPORATION Request for Assignment Assignors: CHILDREN'S MEDICAL CENTER CORPORATION, SCHEPENS EYE RESEARCH INSTITUTE, VA BOSTON HEALTHCARE SYSTEM
Application granted granted Critical
Publication of AU2014219026B2 publication Critical patent/AU2014219026B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2014219026A 2013-02-19 2014-02-19 ABCB5(+) stem cells for treating ocular disease Active AU2014219026B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361766424P 2013-02-19 2013-02-19
US61/766,424 2013-02-19
PCT/US2014/017076 WO2014130518A1 (en) 2013-02-19 2014-02-19 Abcb5(+) stem cells for treating ocular disease

Publications (2)

Publication Number Publication Date
AU2014219026A1 AU2014219026A1 (en) 2015-09-17
AU2014219026B2 true AU2014219026B2 (en) 2018-11-29

Family

ID=51391751

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014219026A Active AU2014219026B2 (en) 2013-02-19 2014-02-19 ABCB5(+) stem cells for treating ocular disease

Country Status (9)

Country Link
US (3) US9801912B2 (enExample)
EP (2) EP3865573A1 (enExample)
JP (2) JP7027026B2 (enExample)
KR (2) KR102385934B1 (enExample)
AU (1) AU2014219026B2 (enExample)
CA (1) CA2901931C (enExample)
DK (1) DK2964238T3 (enExample)
ES (1) ES2860573T3 (enExample)
WO (1) WO2014130518A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2411101C (en) 2000-06-05 2018-01-16 Brigham And Women's Hospital, Inc. A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
WO2007143139A1 (en) 2006-05-31 2007-12-13 The Brigham And Women's Hospital, Inc. Abcb5 positive mesenchymal stem cells as immunomodulators
PT2155248E (pt) 2007-04-12 2015-10-23 Brigham & Womens Hospital Direcionamento a abcb5 para tratameto do cancro
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
ES2796111T3 (es) 2008-11-14 2020-11-25 Brigham & Womens Hospital Inc Métodos terapéuticos relacionados con células madre cancerosas
US9801912B2 (en) 2013-02-19 2017-10-31 Va Boston Healthcare System ABCB5(+) stem cells for treating ocular disease
BR112015028193B8 (pt) * 2013-05-10 2023-04-18 Childrens Medical Center Suporte para cicatrização de feridas
ES2905558T3 (es) 2015-11-13 2022-04-11 Avellino Lab Usa Inc Procedimientos para el tratamiento de las distrofias corneales
KR20210005118A (ko) 2018-04-25 2021-01-13 칠드런'즈 메디컬 센터 코포레이션 Abcb5 리간드 및 기질
US12239672B2 (en) 2018-07-22 2025-03-04 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of ocular diseases
JP7522095B2 (ja) * 2018-07-22 2024-07-24 ミノヴィア セラピューティクス リミテッド 原発性ミトコンドリア病のためのミトコンドリア増強療法
EP3823645B1 (en) 2018-07-22 2024-07-03 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of renal diseases
WO2020021538A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of brain diseases
CA3133939A1 (en) * 2019-04-01 2020-10-08 Stemsight Oy Method for obtaining or maintaining abcg2-positive corneal limbal stem cells
EP4054595A4 (en) * 2019-11-07 2023-11-15 Massachusetts Eye and Ear Infirmary Cultivated autologous limbal epithelial cell (calec) transplantation
EP3842079A1 (en) * 2019-12-24 2021-06-30 Universiteit Antwerpen Ophthalmological device for the treatment of lscd and substrate for use in same
EP4125960A4 (en) * 2020-03-30 2024-04-03 Children's Medical Center Corporation USING STEM CELLS TO TREAT EXCESSIVE INFLAMMATION
US20240335562A1 (en) * 2021-08-04 2024-10-10 Alpine Biotherapeutics Corporation Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders
KR20230129828A (ko) 2022-03-02 2023-09-11 포항공과대학교 산학협력단 안구 후방 질환 또는 손상의 예방 또는 치료용 조성물
KR20230130479A (ko) 2022-03-03 2023-09-12 서울대학교병원 안구건조증 또는 마이봄샘 기능장애의 예방, 개선, 또는 치료용 조성물
CN115074368B (zh) * 2022-06-09 2023-08-08 澳门科技大学 一种耐药型类风湿性关节炎动物模型的构建及其应用
WO2025090565A1 (en) * 2023-10-23 2025-05-01 The Children's Medical Center Corporation Abcb5-targeted stem cell reprogramming and anti-aging strategies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007143139A1 (en) * 2006-05-31 2007-12-13 The Brigham And Women's Hospital, Inc. Abcb5 positive mesenchymal stem cells as immunomodulators

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434075A (en) 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
US5837258A (en) 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
US6231881B1 (en) 1992-02-24 2001-05-15 Anton-Lewis Usala Medium and matrix for long-term proliferation of cells
US5906934A (en) 1995-03-14 1999-05-25 Morphogen Pharmaceuticals, Inc. Mesenchymal stem cells for cartilage repair
ATE439849T1 (de) 1996-04-19 2009-09-15 Osiris Therapeutics Inc Die wiederherstellung und verstärkung von knochen mittels mesenchymalen stammzellen
US6152142A (en) 1997-02-28 2000-11-28 Tseng; Scheffer C. G. Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
DE19722075C1 (de) 1997-05-27 1998-10-01 Wilhelm Dr Med Fleischmann Vorrichtung zur Applikation von Wirkstoffen an einer Wundoberfläche
EP1062321B1 (en) 1998-03-13 2004-12-29 Osiris Therapeutics, Inc. Uses for humane non-autologous mesenchymal stem cells
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US6797269B2 (en) 1998-04-03 2004-09-28 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
EP1082410B1 (en) 1998-05-29 2007-08-01 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
WO2001037922A2 (en) 1999-11-29 2001-05-31 Hill-Rom Services, Inc. Wound treatment apparatus
CA2411101C (en) 2000-06-05 2018-01-16 Brigham And Women's Hospital, Inc. A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
EP1322936A2 (en) 2000-10-03 2003-07-02 California Institute Of Technology Microfluidic devices and methods of use
WO2002083046A1 (en) 2001-04-16 2002-10-24 Pamela Howard Wound dressing system
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US20050186672A1 (en) * 2004-01-27 2005-08-25 Reliance Life Sciences Pvt. Ltd. Tissue system with undifferentiated stem cells derived from corneal limbus
WO2006103685A2 (en) 2005-03-28 2006-10-05 Vision Research Foundation A method for cultivating cells derived from corneal limbal tissue and cells deived from corneal limbal tissue
AU2006304392B2 (en) 2005-10-18 2014-05-01 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
GB0610778D0 (en) 2006-05-31 2006-07-12 Het Nl Kanker I Phosphatidylinositol phospahte and apoptosis
PT2155248E (pt) 2007-04-12 2015-10-23 Brigham & Womens Hospital Direcionamento a abcb5 para tratameto do cancro
US9011840B2 (en) 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
ES2796111T3 (es) 2008-11-14 2020-11-25 Brigham & Womens Hospital Inc Métodos terapéuticos relacionados con células madre cancerosas
WO2010065711A1 (en) 2008-12-04 2010-06-10 Adimab, Inc. An abcb5 epitope and antibodies thereto for the treatment of cancer
GB0908927D0 (en) * 2009-05-22 2009-07-01 Univ Reading The Synthetic graft
WO2013002953A1 (en) 2011-06-01 2013-01-03 The Board Of Trustees Of The University Of Illinois Membrane-scaffold composites for tissue engineering applications
US9801912B2 (en) 2013-02-19 2017-10-31 Va Boston Healthcare System ABCB5(+) stem cells for treating ocular disease
BR112015028193B8 (pt) 2013-05-10 2023-04-18 Childrens Medical Center Suporte para cicatrização de feridas
US20180134771A1 (en) 2015-05-07 2018-05-17 Bioxcel Corporation Novel immunomodulatory therapeutic strategies targeting tumors in cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007143139A1 (en) * 2006-05-31 2007-12-13 The Brigham And Women's Hospital, Inc. Abcb5 positive mesenchymal stem cells as immunomodulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THILL Met al; "Expression of CD 133 and other putative stem cell markers in uveal melanoma."; Melanoma Research (2011), Vol 21, pages 405-416 *

Also Published As

Publication number Publication date
US9801912B2 (en) 2017-10-31
KR20160033068A (ko) 2016-03-25
WO2014130518A1 (en) 2014-08-28
KR102474489B1 (ko) 2022-12-06
DK2964238T3 (da) 2021-03-22
US20150374756A1 (en) 2015-12-31
KR102385934B1 (ko) 2022-04-13
KR20220048048A (ko) 2022-04-19
CA2901931A1 (en) 2014-08-28
ES2860573T3 (es) 2021-10-05
US20180064762A1 (en) 2018-03-08
EP2964238A4 (en) 2016-09-07
US20220118024A1 (en) 2022-04-21
JP2016510727A (ja) 2016-04-11
EP2964238B1 (en) 2021-01-13
JP2019189600A (ja) 2019-10-31
CA2901931C (en) 2023-03-07
EP3865573A1 (en) 2021-08-18
US11129854B2 (en) 2021-09-28
EP2964238A1 (en) 2016-01-13
AU2014219026A1 (en) 2015-09-17
JP7027026B2 (ja) 2022-03-01

Similar Documents

Publication Publication Date Title
US20220118024A1 (en) Abcb5(+) stem cells for treating ocular disease
Ksander et al. ABCB5 is a limbal stem cell gene required for corneal development and repair
CA2828197C (en) Method of producing retinal pigment epithelial cell sheet
Sun et al. Retinal stem/progenitor properties of iris pigment epithelial cells
AU2021204404B2 (en) Phenotype profile of human retinal progenitor cells
JP2016520068A (ja) 創傷治癒および組織工学
JP2025020312A (ja) 多能性幹細胞由来の臨床グレードの角膜内皮細胞の作製および凍結保存
US20090304639A1 (en) Method for preparing an organ for transplantation
Sands Thymic epithelial cell transplantation to the host thymus: Studies in immunomodulation and tolerance induction
Kawasaki et al. JOS. April 2006, Vol. 47. No. 4
Haydari Regenerative potential of corneal endothelium from patients with fuchs endothelial corneal dystrophy

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ FRANK, MARKUS H.; FRANK, NATASHA Y.; KSANDER, BRUCE AND KOLOVOU, PARASKEVI EVI

PC1 Assignment before grant (sect. 113)

Owner name: CHILDREN'S MEDICAL CENTER CORPORATION

Free format text: FORMER APPLICANT(S): SCHEPENS EYE RESEARCH INSTITUTE; VA BOSTON HEALTHCARE SYSTEM; CHILDREN'S MEDICAL CENTER CORPORATION

Owner name: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE

Free format text: FORMER APPLICANT(S): SCHEPENS EYE RESEARCH INSTITUTE; VA BOSTON HEALTHCARE SYSTEM; CHILDREN'S MEDICAL CENTER CORPORATION

Owner name: SCHEPENS EYE RESEARCH INSTITUTE

Free format text: FORMER APPLICANT(S): SCHEPENS EYE RESEARCH INSTITUTE; VA BOSTON HEALTHCARE SYSTEM; CHILDREN'S MEDICAL CENTER CORPORATION

FGA Letters patent sealed or granted (standard patent)